Medical Abortion: Issues of Choice and Acceptability

References

• World Health Organization. Safe Abortion: Technical and Policy Guidance for Health Systems. 2003; WHO: Geneva, 28.
   Google Scholar
• Royal College of Obstetricians and Gynaecologists. The Care of Women Requesting Induced Abortion. National Evidence-Based Clinical Guidelines. London: RCOG, September 2004. Summary at: <www.rcog.org.uk/resources/Public/pdf/abortion_summary.pdf. >. Accessed 27 August 2005.
   Google Scholar
• WHO Essential Medicines Library. At: http://mednet3.who.int/EMLib/DiseaseTreatments/MedicineDetails.aspx?MedIDName=443@mifepristone-misoprostol. >. Accessed 27 August 2005.
   Google Scholar
• L Bjorge. Early pregnancy termination with mifepristone and misoprostol in Norway. Acta Obstetrica Gynecologica Scandinavica. 80(11): 2001; 1056–1061.
   Web of Science ®Google Scholar
• PW Ashok, A Kidd, GM Flett. A randomized comparison of medical abortion and surgical vacuum aspiration at 10-13 weeks gestation. Human Reproduction. 17(1): 2002; 92–98.
   PubMed Web of Science ®Google Scholar
• S Clark. Is medical abortion acceptable to all American women?. Journal of American Medical Women's Association. 55(3 Suppl): 2000; 177–182.
   Google Scholar
• A Hemmerling, F Siedentopf, H Kentenich. Emotional impact and acceptability of medical abortion with mifepristone: a German experience. Journal of Psychosomatic Obstetrics and Gynaecology. 26(1): 2005; 23–31.
   PubMed Web of Science ®Google Scholar
• C Fiala, B Winikoff, L Helstrom. Acceptability of home-use of misoprostol in medical abortion. Contraception. 70(5): 2004; 387–392.
   PubMed Web of Science ®Google Scholar
• E Abdel-Aziz, IM Hassan, H Al-Taher. Assessment of women's satisfaction with medical termination of pregnancy. Journal of Obstetrics and Gynaecology. 24(4): 2004; 429–433.
   Google Scholar
• Iversen OE, Midboe G, Johnsen SL, et al. [Medical abortion-the first Norwegian experiences]. Tidsskrift Nor Laegeforen 2003;Sep:123. [In Norwegian].
   Google Scholar
• H Honkanen, H von Hertzen. Users' perspectives on medical abortion in Finland. Contraception. 65(6): 2002; 419–423.
   Web of Science ®Google Scholar
• JT Jensen. Acceptability of suction curettage and mifepristone abortion in the United States: a prospective comparison study. American Journal of Obstetrics and Gynecology. 182(6): 2000; 1292–1299.
   Web of Science ®Google Scholar
• RH Phelps. Mifepristone abortion in minors. Contraception. 64(6): 2001; 339–343.
   Web of Science ®Google Scholar
• C Steele, S Chiarotti. With everything exposed: cruelty in post-abortion care in Rosario, Argentina. Reproductive Health Matters. 12(24 Suppl.): 2004; 39–46.
   PubMed Web of Science ®Google Scholar
• PW Ashok, A Templeton, PT Wagaarachchi. Factors affecting the outcome of early medical abortion: a review of 4132 consecutive cases. BJOG. 109(11): 2002; 1281–1289.
   PubMed Web of Science ®Google Scholar
• JT Henderson, AC Hwang, CC Harper. Safety of mifepristone abortions in clinical use. Contraception. 72(3): 2005; 175–178.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. FDA Alert for Health Professionals: Mifepristone, 22 July 2005. At: <http://www.fda.gov/cder/drug/InfoSheets/HCP/MifepristoneHCP.pdf. >. Accessed 29 August 2005.
   Google Scholar
• Winikoff B. Global overview of medical abortion. Presentation at Medical Abortion: An International Forum on Policies, Programmes and Services, 17-20 October 2004, Johannesburg.
   Google Scholar
• L Say, R Kulier, M Gulmezoglu. Medical versus surgical methods for first trimester termination of pregnancy. Cochrane Database Systematic Reviews. 25(1): 2005; CD003037.
   Google Scholar
• See for example, Faucher P, Baunot N, Madelenat P. [The efficacy and acceptability of mifepristone medical abortion with home administration misoprostol provided by private providers linked with the hospital: a prospective study of 433 patients]. Gynecology, Obstetrics, Fertility 2005;33(4): 220-27. [In French].
   Google Scholar
• See for example, Hamoda H, Ashok PW, Flett GM, et al. Medical abortion at 9-13 weeks’ gestation: a review of 1076 consecutive cases. Contraception. 2005;71(5):327-32.
   Google Scholar
• B Winikoff, C Ellertson, S Clark. Analysis of failure in medical abortion. Contraception. 54: 1996; 323–327.
   PubMed Web of Science ®Google Scholar
• D Urquhart, A Templeton, F Shinewi. The efficacy and tolerance of mifepristone and prostaglandin in termination of pregnancy of less than 63 days gestation; UK Multicentre Study-final results. Contraception. 55: 1997; 1–5.
   PubMed Web of Science ®Google Scholar
• H Hamoda, PW Ashok, GM Flett. Analgesia requirements and predictors of analgesia use for women undergoing medical abortion up to 22 weeks of gestation. BJOG: An International Journal of Obstetrics and Gynaecology. 111(9): 2004; 996–1000.
   Web of Science ®Google Scholar
• CS Shannon, B Winikoff, R Hausknecht. Multicenter trial of a simplified mifepristone medical abortion regimen. Obstetrics and Gynecology. 105(2): 2005; 345–351.
   Web of Science ®Google Scholar
• Ganatra B. Contrasts and common ground: the context of abortion in Asia. Presentation at Medical Abortion: An International Forum on Policies, Programmes and Services, 17-20 October 2004, Johannesburg.
   Google Scholar
• NT Ngoc. Is home-based administration of prostaglandin safe and feasible for medical abortion? Results from a multisite study in Vietnam. BJOG: An International Journal of Obstetrics and Gynaecology. 111(8): 2004; 814–819.
   Web of Science ®Google Scholar
• S Hajri, J Blum, N Gueddana. Expanding medical abortion in Tunisia: women's experiences from a multi-site expansion study. Contraception. 70(6): 2004; 487–491.
   Web of Science ®Google Scholar
• H Hamoda, HO Critchley, K Paterson. The acceptability of home medical abortion to women in UK settings. BJOG: An International Journal of Obstetrics and Gynaecology. 112(6): 2005; 781–785.
   Web of Science ®Google Scholar
• T Ashima, A Vinita, R Shalini. Early medical abortion: a new regimen up to 49 days' gestation. Australia & New Zealand Journal of Obstetrics & Gynaecology. 45(2): 2005; 137–139.
   Web of Science ®Google Scholar
• Cullingworth L. A cost analysis of service provision of medical abortions in the public health sector at primary and secondary level. Presentation at Medical Abortion: An International Forum on Policies, Programmes and Services, 17-20 October 2004, Johannesburg.
   Google Scholar
• B Ganatra, M Bygdeman, Phan Bich Thuy. From research to reality: the challenges of introducing medical abortion into service delivery in Vietnam. Reproductive Health Matters. 12(24 Suppl): 2004; 105–113.
   Web of Science ®Google Scholar
• DA Grimes, MS Smith, AD Witham. Mifepristone and misoprostol versus dilation and evacuation for midtrimester abortion: a pilot randomised controlled trial. BJOG: An International Journal of Obstetrics and Gynaecology. 111(2): 2004; 148–153.
   Web of Science ®Google Scholar
• Fiala C, Swahn ML, Stephansson O, et al. The effect of non-steroidal anti-inflammatory drugs on medical abortion with mifeprisone and misoprostol at 13-22 weeks gestation. Human Reproduction 2005; August 11 (Abstract only, e-publication).
   Google Scholar
• PW Ashok, A Templeton, PT Wagaarachchi. Midtrimester medical termination of pregnancy: a review of 1002 consecutive cases. Contraception. 69(1): 2004; 51–58.
   PubMed Web of Science ®Google Scholar
• H Espinoza, K Abuabara, C Ellertson. Physicians' knowledge and opinions about medication abortion in four Latin American and Caribbean region countries. Contraception. 70(2): 2004; 127–133.
   PubMed Web of Science ®Google Scholar
• C Joffe, S Yanow. Advanced practice clinicians as abortion providers: current developments in the United States. Reproductive Health Matters. 12(24 Suppl.): 2004; 198–206.
   Web of Science ®Google Scholar